New York, USA
Patterson Belknap Webb & Tyler is pleased to announce that the firm has been recognized by Chambers High Net Worth 2025 in the following practice areas: Art and Cultural Property Law – USA-Nationwide Private Wealth Law – New York The firm also received individual recognitions by Chambers in both practice areas: Anne-Laure Alléhaut, Jo Backer Laird, and John Sare were ranked in the Art and Cultural Property Law practice area in the USA
New York, USA
Partner Julie Simeone has been profiled in Law.com's "How I Made Partner" Q&A series. In the article, Ms. Simeone reflects on the factors that led her to choose Patterson Belknap at the beginning of her legal career and the breadth of experience that she has gained across different practice areas throughout her time at the firm
New York, USA
Partners Kathryn Bi, Lachlan Campbell-Verduyn, and Clint Morrison have been ranked in the 2025 edition of The Lawdragon 500 X – The Next Generation, a guide evaluating which young lawyers and law practices have had a significant impact in the field and determining the "next generation of legal leaders in America and around the world
New York, USA
On July 8, 2025, Patterson Belknap earned a significant victory on behalf of our clients, Johnson & Johnson (J&J) subsidiaries Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV (Janssen), in a Hatch-Waxman patent infringement litigation concerning Teva’s and Mylan’s proposed generic versions of Janssen’s blockbuster, long-acting-injectable antipsychotic drug Invega Sustenna. The U.S
New York, USA
Patterson Belknap has been ranked fourth in The American Lawyer’s 2025 Pro Bono Scorecard. The rankings assess pro bono efforts among Am Law 200 firms and are based on both the average number of pro bono hours per attorney and the percentage of attorneys performing more than 20 hours of pro bono service in 2024
New York, USA
On July 7, the firm, along with co-counsel at New York Legal Assistance Group (NYLAG), obtained an important victory for disabled New Yorkers at risk of losing access to critical in-home care services through the Consumer Directed Personal Assistance Program (CDPAP), which allows Medicaid patients to select and train their own personal aides
New York, USA
On June 23, 2025, Patterson Belknap successfully obtained a dismissal of a putative class action complaint on behalf of our client, InComm Financial Services, Inc. ("InComm"), in the Southern District of New York. Plaintiff alleged that InComm’s Vanilla Prepaid Gift Cards were deceptively marketed because the “VISA” logo on the card suggested the cards were immune to third-party fraud and did not explicitly detail the risks of package tampering fraud
New York, USA
The 2025 Edition of The Legal 500 United States has ranked Patterson Belknap as a top-tier firm for Advertising and Marketing: Litigation and Tax: Not-for-Profit (Fortune 1000 Private Foundations, National Trade Associations, and Charities). The publication has also listed Of Counsel Robert J. Cleary in its Corporate Investigations and White-Collar Criminal Defense "Hall of Fame
New York, USA
Litigation partner Alejandro Cruz has been appointed to serve on the American Bar Association (ABA)'s Lawyers' Professional Liability Committee. The Committee serves as a resource to ABA members for guidance on legal malpractice claims, insurance for lawyers, and malpractice prevention tips. Mr. Cruz's appointment is effective as of August 2025. Mr. Cruz represents clients in complex commercial litigation, as well as in arbitrations, mediations, and investigations
New York, USA
Patterson Belknap Webb & Tyler LLP is pleased to announce that 19 of our attorneys and 7 of our practice areas have been recognized in the newly released Chambers USA 2025. Chambers is a premier professional legal research company delivering detailed rankings and insights into the world’s leading lawyers and law firms
New York, USA
On May 12, 2025, the firm, along with co-counsel ACLU Florida, obtained a significant victory for Naples Pride, protecting the organization's First Amendment right to host a drag performance in a Naples, Florida public park as part of its 2025 LGBTQ+ Pridefest celebration. Starting in 2023, the City of Naples made clear that if Naples Pride attempted to apply for a permit to host a family-friendly drag performance in an outdoor public space, it would be rejected
New York, USA
On April 21, 2025, Patterson Belknap obtained a significant victory for our client, Gilead Sciences Inc., when the United States District Court for the Eastern District of New York granted the firm’s motion to enforce a non-party subpoena against a law firm representing an alleged distributor of counterfeit Gilead-branded HIV medicines
New York, USA
On April 10, the firm, along with co-counsel at New York Legal Assistance Group (NYLAG), obtained an important victory for disabled New Yorkers at risk of losing access to critical in-home care services through the Consumer Directed Personal Assistance Program (CDPAP), which allows Medicaid patients to select and train their own personal aides
New York, USA
On April 11, 2025, Patterson Belknap secured a significant victory for our clients, Johnson & Johnson subsidiaries DePuy Synthes, Inc., Synthes USA, LLC, Synthes USA Products, LLC, and DePuy Synthes Sales, Inc., in a medical device patent infringement litigation concerning DePuy Synthes’ TFN-ADVANCED™ Proximal Femoral Nailing (“TFNA”) system
New York, USA
Patterson Belknap has joined the amicus briefs supporting Perkins Coie, Jenner & Block, WilmerHale, and Susman Godfrey in their legal actions challenging the Executive Orders issued against those firms. Our firm has a history of defending the rule of law, and we are proud to do it again now. Our decision to participate as an amicus had nothing to do with politics or partisan ideologies
New York, USA
On March 28, 2025, Patterson Belknap secured another significant victory for our clients, Johnson & Johnson subsidiaries Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research & Development, LLC, in a Hatch-Waxman patent infringement litigation regarding Mylan Laboratories’ proposed generic versions of Janssen’s Invega Trinza® product
New York, USA
On March 11, 2025, Patterson Belknap and co-counsel at Davis Polk & Wardwell LLP obtained a significant jury-trial victory for our client, marketing executive Dela Yador, in a multi-million dollar commercial litigation involving breach of contract. The Patterson Belknap team was led by partner Kathryn Bi and included attorneys Catherine Djang, George Harris, and Gregory Diskant. Mr. Yador filed the case after his partner, Jason Mowatt, wrongfully excluded Mr
New York, USA
Patterson Belknap has been shortlisted by Benchmark Litigation in its annual US Awards for the New York category. According to Benchmark, this list recognizes the country’s most distinguished litigation firms “for their exemplary work over the past 12 months
New York, USA
Ms. Bi’s arrival enhances bench strength of firm’s Patent Litigation Practice Patterson Belknap is pleased to announce that Kathryn Bi has joined the firm as a Partner in its Litigation department and as a member of the Patent Litigation practice. Ms. Bi helps clients resolve their toughest intellectual property and commercial cases, focusing her practice on complex technology disputes. She has successfully represented tech companies in numerous high-stakes patent cases. Ms
New York, USA
On December 31, 2024, Patterson Belknap obtained a significant victory for our client Johnson & Johnson (J&J) in a products liability case concerning cosmetic talc
New York, USA
On November 21, 2024, Patterson Belknap obtained a significant victory on behalf of our clients, Johnson & Johnson (J&J) subsidiaries Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV (Janssen), in a Hatch-Waxman patent infringement litigation concerning Teva’s and Mylan’s proposed generic versions of Janssen’s long-acting-injectable antipsychotic drug Invega Sustenna
New York, USA
On November 21, 2024, Patterson Belknap obtained a significant victory on behalf of our clients, Johnson & Johnson (J&J) subsidiaries Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV (Janssen), in a Hatch-Waxman patent infringement litigation concerning Teva’s and Mylan’s proposed generic versions of Janssen’s long-acting-injectable antipsychotic drug Invega Sustenna
New York, USA
On Tuesday, November 12, a jury in the U.S. District Court for Eastern District of Virginia found a Virginia-based government contractor liable for its role in the torture of the firm's clients at Abu Ghraib prison in Iraq, ordering the company to pay $42 million in damages to three Iraqi prisoners. The case is the first of its kind to have made it to trial, and the first verdict holding a government contractor legally responsible for torture at the infamous prison
New York, USA
On Tuesday, November 12, a jury in the U.S. District Court for Eastern District of Virginia found a Virginia-based government contractor liable for its role in the torture of the firm's clients at Abu Ghraib prison in Iraq, ordering the company to pay $42 million in damages to three Iraqi prisoners. The case is the first of its kind to have made it to trial, and the first verdict holding a government contractor legally responsible for torture at the infamous prison
New York, USA
On November 12, 2024, Patterson Belknap obtained a significant victory on behalf of our client, InComm Financial Services, Inc. (“InComm”), in a false advertising case in the Central District of California. The Court found that plaintiffs' counsel exhibited a "stunning, nearly two-year lack of diligence" in pursuing their claims, and accordingly ordered them to pay attorneys’ fees to InComm